Anaveon presents compelling data from the Phase I/II study of ANV419 during the AACR Annual Meeting 2022 - ANV419 is very well-tolerated and demonstrates exceptional safety with strong pharmacodynamic effects and excellent IL-2Rβγ selectivity - - A Phase II program of ANV419 has been initiated in...

Anaveon to raise CHF 110 million in oversubscribed Series B financing - Leading international syndicate led by Forbion and corner-stoned by founding investor Syncona- Confirms depth of support for Anaveon’s approach to developing engineered cytokines in multiple...

Jeito Capital co-leads $110 Million Series A Financing in Neogene Therapeutics Jeito Capital co-leads $110 Million Series A Financing in Neogene Therapeutics Neogene becomes Jeito Capital’s first investment following the fund I launch in January 2020Round co-led by Jeito...